Immunovant, Inc. (IMVT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Immunovant, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Immunovant, Inc. (IMVT) has returned -2.28% so far this year and 45.35% over the past 12 months.

Based on dividend-adjusted daily data since Dec 19, 2019, IMVT's average daily return is +0.14%, while the average monthly return is +2.63%. At this rate, your investment would double in approximately 2.2 years.

Historically, 43% of months were positive and 57% were negative. The best month was Oct 2022 with a return of +100.7%, while the worst month was Feb 2021 at -59.6%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, IMVT closed higher 49% of trading days. The best single day was Sep 26, 2023 with a return of +97.0%, while the worst single day was Feb 2, 2021 at -42.1%.

Immunovant, Inc. has an annualized alpha of 24.99%, beta of 0.97, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since December 20, 2019.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (32.11%) than losses (27.02%) — typical of diversified or defensive assets.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IMVT ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Immunovant, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immunovant, Inc. was 93.59%, occurring on Jun 16, 2022. The portfolio has not yet recovered.

The current Immunovant, Inc. drawdown is 52.87%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Immunovant, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Immunovant, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.